ProteoNic licenses to pharmaceutical and biotechnology companies as well as to CDMOs. Licenses are provided on a non-exclusive, world-wide basis.
ProteoNic licenses to pharmaceutical and biotechnology companies as well as to CDMOs. Licenses are provided on a non-exclusive, world-wide basis.
Capture value, license ProteoNic technology
ProteoNic licenses to pharmaceutical and biotechnology companies as well as to CDMOs. Licenses are provided on a non-exclusive, world-wide basis.
ProteoNic offers two licensing models:
Product licenses have upfront and milestone payments per product for a specified number of products. Platform licenses are provided for an unlimited number of products. Payment terms may vary from lump sum upfront buy-out payments to milestone-based payment schedules. Licensing terms are flexible and royalty-free.
We provide flexible, non-exclusive, royalty-free licenses and offer different payment options, ranging from lump sum buy-out to milestone-based payment schedules
Test 2G UNic® in a proof-of-concept study, for a limited time period and number of products We offer two options: using our technology in your vector, or integrating your gene into our fully optimized 2G UNic® vector:
ProteoNic transfers the technology to you or your CDMO for transfection, stable pool generation, clone generation and analysis.
Commercial terms are pre-agreed, before execution of any evaluation study
Main options:
If required, ProteoNic staff can remain available for consultation throughout the process
We provide access to our technology irrespective of company size or market segment. Our licensees include large pharma, biotech and CDMOs, as well as smaller players. Ultimately, our licensees provide validation of our technology and commercial model.
Designed for use across the therapeutic protein production industry.
Suitable for diverse molecule types and mammalian expression systems.
Proven by third parties to deliver severalfold productivity increases.
Available through evaluation, commercial licensing and CDMO partnerships.
Adopted by pharma, biotech and CDMO partners worldwide.
